GHRS stock sentiment todayGH Research PLC
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
GHRS
GH Research PLCA high-upside clinical lottery ticket in the psychedelic space, currently in a 'wait-and-see' period regarding Phase 2b data and regulatory clarity.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GHRS. Not financial advice.
Price · last 12 months
Gossip
The narrative centers on GHRS being a 'dark horse' in the psychedelic medicine race. While it lacks the mainstream buzz of Cybin or Compass, it is favored by institutional biotech specialists for its unique 5-MeO-DMT delivery. Sentiment is currently muted due to a lack of near-term catalysts and broader sector fatigue following the FDA's rejection of Lykos Therapeutics' MDMA therapy.
- ·Ultra-rapid onset of 5-MeO-DMT vs. longer psilocybin sessions
- ·Anticipation of Phase 2b data for TRD (Treatment-Resistant Depression)
- ·Regulatory overhang on the entire psychedelic sector
- ·Low float volatility
Financial
As a clinical-stage biotech, GHRS has no revenue, but its balance sheet is exceptionally lean for the sector. They maintain a significant cash runway that extends into 2026, minimizing the immediate risk of dilutive equity raises compared to peers.
- ·Cash and equivalents: ~$215M (sufficient for current clinical pipeline)
- ·Net Loss: Widening as clinical trials scale, but managed burn rate
- ·Debt: Minimal to no long-term debt
- ·Market Cap: ~$1.4B (reflective of high speculative premium)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Binary clinical trial outcome: Phase 2b failure would be catastrophic for valuation
- ·Regulatory hurdles for 5-MeO-DMT administration (DEA scheduling)
- ·Small patient sample sizes in early trials leading to potential 'efficacy dilution' in larger studies
Peer temperature
How direct competitors stack up against GHRS right now.
- HOTCMPSCompass Pathways
HOTTER — Further along in Phase 3 trials with a more established regulatory roadmap for COMP360.
See full analysis → - NEUTRALCYBNCybin Inc.
SIMILAR — While Cybin has a more aggressive PR strategy, GHRS has a stronger cash-to-burn ratio.
See full analysis → - COLDATAIATAI Life Sciences
COLDER — Faces a fragmented pipeline and high operational complexity compared to GHRS's focused 5-MeO-DMT approach.
See full analysis →
- GHRS-3.1%
- CMPS-2.3%
- CYBN—
- ATAI+2.4%
Analyst price target
Consensus average of 9 analysts · median 40.00
Source: StockAnalysis.com · updated 2026-08-31
AI-generated analysis for informational purposes only. Not financial advice.